Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 544 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HIV in Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults

NCT00054860
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

NCT04983030
View directory record Official record
Conditions
HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired, Sexually Transmitted Diseases, Viral, Retroviridae Infections
Interventions
Ad26.Mos4.HIV, MVA-BN-HIV, PGT121, PGDM1400, VRC07-523LS
Biological
Lead sponsor
Boris Juelg, MD PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Orlando, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Recruiting Not applicable Interventional

The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV

NCT07226128
View directory record Official record
Conditions
HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
Interventions
Internet cognitive behavioral therapy (iCBT-D), Active Control (AC)
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 4 Interventional

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

NCT00233883
View directory record Official record
Conditions
HIV Infections
Interventions
enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Long Beach, California • Los Angeles, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

NCT00002173
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Immunogen
Biological
Lead sponsor
The Immune Response Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional

Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy

NCT00109603
View directory record Official record
Conditions
HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 7, 2026, 1:14 AM EDT
Completed No phase listed Observational

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854
View directory record Official record
Conditions
HIV-1, HIV Infections
Interventions
Blood draw
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

NCT01440569
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
COBI, DRV, NRTIs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
48
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults

NCT00097838
View directory record Official record
Conditions
HIV Infections
Interventions
AVX101, placebo
Biological · Other
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

Feasibility of SBIRT-PN

NCT03057119
View directory record Official record
Conditions
Substance Use, HIV/AIDS, Older Adults, Behavioral Intervention, Infectious Disease
Interventions
Psycho-educational content (5 Minutes), Readiness Assessment (10 minutes), Goal-Setting (5 minutes), Identifying and prioritizing needs (5 minutes), Explanation of Peer Navigator and Session wrap (5 minutes)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Jacksonville, Florida • Lake City, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Reducing Drug Use and HIV Risk in Drug-dependent Adults Arrested for Prostitution

NCT01560221
View directory record Official record
Conditions
Substance-related Disorders, HIV Risk Behavior
Interventions
Therapeutic Workplace, Methadone, Buprenorphine
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection

NCT00109629
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PlusCare: Mobile Platform to Increase Linkage to Care in Adolescents Living With HIV/AIDS

NCT03758066
View directory record Official record
Conditions
HIV/AIDS
Interventions
PlusCare
Device
Lead sponsor
Dimagi Inc.
Industry
Eligibility
13 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults

NCT00428337
View directory record Official record
Conditions
HIV Infections
Interventions
EP-1233, MVA-mBN32
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
San Francisco, California • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Recruiting Phase 2 Interventional

Propranolol for the Treatment of Kaposi Sarcoma in Adults

NCT06445166
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Propranolol Hydrochloride
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 7, 2026, 1:14 AM EDT
Completed No phase listed Observational

Correlates of Oral Human Papillomavirus Infection in Adolescents and Young Adults With Behaviorally Acquired HIV

NCT01492842
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 7, 2026, 1:14 AM EDT
Not listed Not applicable Interventional

Telephone Counseling to Enhance the Quality and Safety of Romantic and Sexual Relationships in People Living and Aging With HIV

NCT03004170
View directory record Official record
Conditions
HIV Seropositivity
Interventions
Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training, Telephone-Administered Coping Effectiveness Training
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional Results available

Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption

NCT02463227
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Birmingham, Alabama • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

NCT03272347
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo to Islatravir, Doravirine, Placebo to Doravirine, Lamivudine, Placebo to Lamivudine, Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Placebo to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate, Doravirine/Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 1 Interventional

Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy

NCT00107549
View directory record Official record
Conditions
HIV Infections
Interventions
rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]), rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2009
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults

NCT01968551
View directory record Official record
Conditions
HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
56
States / cities
Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Entertainment education, video
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 25 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Not applicable Interventional Results available

mHealth App for Engagement in Care Among Youth Living With HIV

NCT03587857
View directory record Official record
Conditions
HIV/AIDS, Mobile Health, Young Adults
Interventions
Mobile Health Application
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 29 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 7, 2026, 1:14 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

NCT00830804
View directory record Official record
Conditions
HIV-1 Infections
Interventions
Raltegravir, Darunavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 7, 2026, 1:14 AM EDT